3 completed, 2 unknown, 1 active not recruiting, 1 recruiting. 9 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 3, Unknown 2, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Physiological Effects of Drugs: new trials by email Literature Review of Physiological Effects of Drugs trials Research Report on Physiological Effects of Drugs
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg), Placebo - Suicide, Depressive Disorder, Treatment-Resistant | Phase 2 | Recruiting | National Institute of Mental Health (NIMH) | 50 | 2024-11-06 | 2026-10-05 |
| Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study Ad26.ZEBOV, MVA-BN-Filo - Virus Diseases, Hemorrhagic Fever, Ebola | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 133 | 2022-09-19 | 2025-05-11 |
| Propranolol on Post Stroke Immune Status and Infection Propranolol, Ceftriaxone - Stroke, Cerebrovascular Disorders | Phase 2 | Unknown | Tianjin Medical University General Hospital | 45 | 2022-06-01 | 2022-05-16 |
| The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia Sitagliptin, Danazol - Immune Thrombocytopenia, Blood Coagulation Disorders | Phase 2 | Unknown | Peking University People's Hospital | 120 | 2021-06-01 | 2022-04-29 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 CYNK-001 - Coronavirus, Coronavirus Infection | Phase 1 / Phase 2 | Terminated | Celularity Incorporated | 7 | 2020-09-02 | 2026-06-26 |
| Omalizumab to Accelerate a Symptom-driven Multi-food OIT Omalizumab 16mg/kg, Omalizumab 8mg/kg, Placebo - Food IgE-mediated Allergy, Immunotherapy | Phase 2 | Active not recruiting | Philippe Bégin | 90 | 2019-11-11 | 2024-11-27 |
| Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma. QAW039 - Asthma, Asthma, Bronchial | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2019-10-15 | 2020-05-14 | |
| Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI Alirocumab, Sham Control - ST Elevation Myocardial Infarction, Acute Coronary Syndrome | Phase 2 | Completed | Population Health Research Institute | 97 | 2019-03-11 | 2022-04-11 |
| Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes Diamyd, Vitamin D, Placebo for Diamyd - Diabetes Mellitus, Type 1, Diabetes Mellitus | Phase 2 | Completed | Diamyd Medical AB | 109 | 2017-12-20 | 2023-01-09 |
Immune System Diseases (2) · Infections (2) · RNA Virus Infections (2) · Virus Diseases (2) · Acute Coronary Syndrome (1) · Asthma (1) · Autoimmune Diseases (1) · Behavioral Symptoms (1) · Blood Coagulation Disorders (1) · Brain Diseases (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Coronaviridae Infections (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Nutritional and Metabolic Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Vascular Diseases (2) · Autoimmune Diseases (1) · Behavior (1) · Blood Platelet Disorders (1) · Bronchial Diseases (1) · Cardiovascular Diseases (1) · Cytopenia (1) · Heart Diseases (1) · Hemorrhage (1)
6-hydroxynorketamine (1) · Ceftriaxone (1) · Danazol (1) · Omalizumab (1) · Propranolol (1) · Sitagliptin Phosphate (1) · Vitamin D (1) · alirocumab (1) · fevipiprant (1)
Celularity Incorporated (1) · Diamyd Medical AB (1) · London School of Hygiene and Tropical Medicine (1) · National Institute of Mental Health (NIMH) (1) · Novartis Pharmaceuticals (1) · Peking University People's Hospital (1) · Philippe Bégin (1) · Population Health Research Institute (1) · Tianjin Medical University General Hospital (1)
Canada (2) · China (2) · United States (2) · Czechia (1) · Netherlands (1) · Sierra Leone (1) · Spain (1) · Sweden (1)
Carlos A Zarate, M.D. (1) · Corey Casper, MD MPH (1) · Deborah Watson-Jones, PhD (1) · Johnny Ludvigsson, MD, Prof (1) · Shamir Mehta, MD MSc FRCPC (1) · Xiao-hui Zhang, MD (1)
PMID 32328115, PMID 34021020, PMID 35665810, PMID 36349701, PMID 36817467
2017 (1)